JEFFREY STARKE to Cost-Benefit Analysis
This is a "connection" page, showing publications JEFFREY STARKE has written about Cost-Benefit Analysis.
Connection Strength
0.119
-
Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children. Int J Tuberc Lung Dis. 2014 Sep; 18(9):1057-61.
Score: 0.098
-
Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis. 2013 Jan; 61(1):22-32.
Score: 0.021